China is set for the first domestic listing from a loss-making company after suzhou ZELCEN BLOPHARMACEUTICALS raised Rmb2.03bn (US$295m) from a Shanghai Star IPO last week, marking another important milestone in the A-share market. The listing of unprofitable companies was prohibited in China until the launch of the Shanghai Star market last year.
展开▼